BACKGROUND: We investigated associations between statin use begun before prostate cancer (PCa) diagnosis and PCa recurrence/progression and PCa-specific mortality (PCSM) in a prospective, population-based cohort study. METHODS: The analysis included 1,001 PCa patients diagnosed in 2002-2005 in King County, Washington. Statin use was assessed at the time of diagnosis using a detailed in-person interview. Prostate cancer recurrence/progression events and cause-specific survival were ascertained from a follow-up survey and the SEER registry. Multivariable competing risk and Cox proportional hazards regression models were used to assess the risk of PCa outcomes according to categories of statin use. RESULTS: Of the 1,001 PCa patients in our study, 289 men were ever users of statin drugs. During follow-up, we identified 151 PCa recurrence/progression events and 123 total deaths, including 39 PCa-specific deaths. In unadjusted analysis, the risk of PCSM was significantly lower for statin users compared to non-users (1% vs. 5% at 10 years; P < 0.01). In multivariable analysis, the adjusted hazard ratio of PCSM for statin users versus non-users was 0.19 (95% CI: 0.06, 0.56). Statin use was not associated with overall PCa recurrence/progression and other-cause mortality. CONCLUSIONS: Statin use begun before PCa diagnosis was unrelated to PCa recurrence/progression but was associated with a decrease in risk of PCSM.
BACKGROUND: We investigated associations between statin use begun before prostate cancer (PCa) diagnosis and PCa recurrence/progression and PCa-specific mortality (PCSM) in a prospective, population-based cohort study. METHODS: The analysis included 1,001 PCa patients diagnosed in 2002-2005 in King County, Washington. Statin use was assessed at the time of diagnosis using a detailed in-person interview. Prostate cancer recurrence/progression events and cause-specific survival were ascertained from a follow-up survey and the SEER registry. Multivariable competing risk and Cox proportional hazards regression models were used to assess the risk of PCa outcomes according to categories of statin use. RESULTS: Of the 1,001 PCa patients in our study, 289 men were ever users of statin drugs. During follow-up, we identified 151 PCa recurrence/progression events and 123 total deaths, including 39 PCa-specific deaths. In unadjusted analysis, the risk of PCSM was significantly lower for statin users compared to non-users (1% vs. 5% at 10 years; P < 0.01). In multivariable analysis, the adjusted hazard ratio of PCSM for statin users versus non-users was 0.19 (95% CI: 0.06, 0.56). Statin use was not associated with overall PCa recurrence/progression and other-cause mortality. CONCLUSIONS: Statin use begun before PCa diagnosis was unrelated to PCa recurrence/progression but was associated with a decrease in risk of PCSM.
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Emil Scosyrev; Scott Tobis; Heather Donsky; Guan Wu; Jean Joseph; Hani Rashid; Edward Messing Journal: BJU Int Date: 2012-09-27 Impact factor: 5.588
Authors: Mark A Moyad; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Robert W Galbreath; Brian Kurko; Edward Adamovich Journal: Urology Date: 2005-12 Impact factor: 2.649
Authors: Ilir Agalliu; Claudia A Salinas; Philip D Hansten; Elaine A Ostrander; Janet L Stanford Journal: Am J Epidemiol Date: 2008-06-12 Impact factor: 4.897
Authors: Marie-France Demierre; Peter D R Higgins; Stephen B Gruber; Ernest Hawk; Scott M Lippman Journal: Nat Rev Cancer Date: 2005-12 Impact factor: 60.716
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: J A Gordon; A Midha; A Szeitz; M Ghaffari; H H Adomat; Y Guo; T L Klassen; E S Guns; K M Wasan; M E Cox Journal: Prostate Cancer Prostatic Dis Date: 2015-08-04 Impact factor: 5.554
Authors: June M Chan; Stacey A Kenfield; Alan Paciorek; Elizabeth A Platz; Edward L Giovannucci; Meir J Stampfer Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-19 Impact factor: 4.254
Authors: Mahmoud A Alfaqih; Erik R Nelson; Wen Liu; Rachid Safi; Jeffery S Jasper; Everardo Macias; Joseph Geradts; J Will Thompson; Laura G Dubois; Michael R Freeman; Ching-Yi Chang; Jen-Tsan Chi; Donald P McDonnell; Stephen J Freedland Journal: Cancer Res Date: 2017-01-27 Impact factor: 12.701
Authors: Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland Journal: Nat Rev Urol Date: 2016-10-25 Impact factor: 14.432
Authors: Alison M Mondul; Corinne E Joshu; John R Barber; Anna E Prizment; Nrupen A Bhavsar; Elizabeth Selvin; Aaron R Folsom; Elizabeth A Platz Journal: Cancer Prev Res (Phila) Date: 2018-10-16